Hikma’s USA subsidiary launches Zinecard generic, Dexrazoxane, for breast cancer
April 20, 2018Hikma Pharmaceuticals has launched Dexrazoxane for Injection, 250mg and 500mg vials, the generic equivalent to Zinecard, through its US wholly-owned subsidiary West-Ward Pharmaceuticals Corp.
West-Ward’s Dexrazoxane for Injection is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in certain women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin therapy to maintain tumor control. It should not be used with the initiation of doxorubicin therapy.
Riad Mechlaoui, Chief Executive Officer of Injectables said that Dexrazoxane should reduce the shortage of this product in the US market.
According to IQVIA, US sales of Dexrazoxane for Injection, 250mg and 500mg, were approximately $15 million in the 12 months ending February 2018.
